Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 4, 2013, Pages 327-333

  Wang, Zhengzhong ^a,b   Dai, Hongyan ^b   Xing, Mingqing ^b   Yu, Zhongxiang ^b   Lin, Xianru ^b   Wang, Shoudong ^b   Zhang, Junyi ^b   Hou, Fangjie ^b   Ma, Ying ^b   Ren, Yongqiang ^b   Tan, Kai ^b   Wang, Yanping ^b   Ge, Zhiming ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

high sensitivity C reactive protein; interleukin 6; monocyte chemotactic protein 1; non ST segment elevation acute coronary syndrome; percutaneous coronary intervention; rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; ROSUVASTATIN; TROPONIN I;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

HIGH-SENSITIVITY C-REACTIVE PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES;

EID: 84876728545     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412474346     Document Type: Article

References (36)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4s). Lancet. 1994 ; 344 (8934). 1383-1389
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
3. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005 ; 45: 89-118
4. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-q-wave myocardial infarction. Circulation. 2002 ; 106 (17). 2180-2183
5. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002 ; 105 (6). 691-696
6. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the armyda (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation. 2004 ; 110 (6). 674-678
7. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the armyda-acs randomized trial. J Am Coll Cardiol. 2007 ; 49 (12). 1272-1278
8. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the armyda-recapture (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol. 2009 ; 54 (6). 558-565
9. Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009 ; 137 (3). 246-251
10. Yun KH, Oh SK. Rhee SJ, et al. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2011 ; 146 (1). 68-72
11. Sardella G, Conti G, Donahue M, et al. Rosuvastatin pre-treatment in patients undergoing elective pci to reduce the incidence of myocardial periprocedural necrosis. The roma trial. Catheter Cardiovasc Interv. 2013 ; 81 (1). E36 - E43
12. Pitt B, Loscalzo J, Monyak J, et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the lunar study). Am J Cardiol. 2012 ; 109 (9). 1239-1246
13. Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the archimedes model. J Med Econ. 2012 ; 15 (6). 1118-1129
14. Davignon J.. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 ; 109 (23 suppl 1). III39 - III43
15. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002 ; 23 (11). 869-876
16. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003 ; 42 (8). 1406-1411
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996 ; 335 (14). 1001-1009
18. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the statin stemi trial. JACC Cardiovasc Interv. 2010 ; 3 (3). 332-339
19. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (naples) ii trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009 ; 54 (23). 2157-2163
20. Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-prove it: a prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) substudy. J Am Coll Cardiol. 2009 ; 54 (24). 2290-2295
21. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002 ; 22 (10). 1524-1534
22. Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des. 2007 ; 13 (17). 1771-1786
23. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces nf-kappab activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999 ; 147 (2). 253-261
24. Haloui M, Meilhac O, Jandrot-Perrus M, et al. Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur J Pharmacol. 2003 ; 474 (2-3). 175-184
25. Loppnow H, Zhang L, Buerke M, et al. Statins potently reduce the cytokine-mediated il-6 release in smc/mnc cocultures. J Cell Mol Med. 2011 ; 15 (4). 994-1004
26. Cheng SM, Lai JH, Yang SP, et al. Modulation of human t cells signaling transduction by lovastatin. Int J Cardiol. 2010 ; 140 (1). 24-33
27. Shimizu K, Aikawa M, Takayama K, et al. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation. 2003 ; 108 (17). 2113-2120
28. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 ; 22 (7). 1194-1199
29. Tonkin A, Aylward P, Colquhoun D, et al. for Long-Term Intervention Pravastatin Ischaemic. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 ; 339 (19). 1349-1357
30. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of afcaps/texcaps. Air force/texas coronary atherosclerosis prevention study. JAMA. 1998 ; 279 (20). 1615-1622
31. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207
32. Rebeiz AG, Zoghbi E, Harb R, et al. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. J Interv Cardiol. 2009 ; 22 (2). 169-174
33. Sanchez-Margalet V, Cubero JM, Martin-Romero C, et al. Inflammatory response to coronary stent implantation in patients with unstable angina. Clin Chem Lab Med. 2002 ; 40 (8). 769-774
34. Bonz AW, Lengenfelder B, Jacobs M, et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein iib/iiia receptor antagonism. Am Heart J. 2003 ; 145 (4). 693-699
35. Kwaijtaal M, van Diest R, Bar FW, et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis. 2005 ; 182 (2). 341-348
36. von der Thusen JH, Kuiper J, van Berkel TJ, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003 ; 55 (1). 133-166